In an in vitro model of MS, inhibited miR-155 expression reduced the expression of CD4 + T cell effector cytokines IFN-γ and IL-17, contributing to the view that miR-155 might be a valuable target in MS therapy (Jevtić et al., 2015). Here, CD4 is linked to myeloid sarcoma.